Merck, Inc.
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 350
- Registration Number
- NCT06721156
- Locations
- 🇺🇸
Banner Alzheimer's Institute ( Site 0110), Phoenix, Arizona, United States
🇺🇸Irvine Clinical Research ( Site 0104), Irvine, California, United States
🇺🇸Anderson Clinical Research ( Site 0164), Redlands, California, United States
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1046
- Registration Number
- NCT06717347
- Locations
- 🇺🇸
Cancer Blood and Specialty Clinic ( Site 0109), Los Alamitos, California, United States
🇺🇸Cancer Care Specialists of Illinois ( Site 0152), O'Fallon, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology ( Site 0149), Fort Wayne, Indiana, United States
A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06703463
- Locations
- 🇺🇸
Celerion (Site 0002), Lincoln, Nebraska, United States
A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT06701305
- Locations
- 🇺🇸
QPS-MRA, LLC (Site 0001), South Miami, Florida, United States
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT06699329
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06699355
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06698016
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc. (Site 0001), Overland Park, Kansas, United States
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
- Conditions
- Lung CancerNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06698042
- Locations
- 🇯🇵
Osaka International Cancer Institute ( Site 4005), Osaka, Japan
🇺🇸Illinois Cancer Care ( Site 0101), Peoria, Illinois, United States
🇺🇸Montefiore Medical Center ( Site 0104), Bronx, New York, United States
A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06691906
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 19
- Registration Number
- NCT06692647
- Locations
- 🇺🇸
Labcorb CRU, Madison (Site 0001), Madison, Wisconsin, United States